Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

ependent claim that was finally granted in the '090 patent has two parts -- part "(a)" and part "(b)" -- and they must both be satisfied in order to find any infringement.  The claim provides as follows:

1.  A method for treating a glioma in a mammal, the method comprising:

(a)     administering at least one vaccination of dendritic cells ("DC") to said mammal suffering from a glioma, wherein the [sic] at least one vaccination of DC comprises autologous DC that present autologous glioma antigens;

and

(b)    after glioma recurrence following (a), administering a regimen of chemotherapy to said mammal, wherein said regimen of chemotherapy includes the administration of at least one chemotherapeutic agent selected from the group consisting of temozolomide, procarbazine, vincristine, BCNU, CCNU, thalidomide, irinotecan, isotretinoin, imatinib, etoposide, and combinations thereof.

Thus, this patent claim only covers situations where the method of treatment used includes BOTH steps (a) AND (b).     

  • The 090 patent does not cover the combination of a dendritic cell based vaccine treatment combined either before or concurrently with chemotherapy at the recurrence of cancers of the central nervous system. 

Furthermore, to be within the scope of the '090 patent, it is not even enough to do both steps (a) and (b)….. the steps must be performed in a precise sequence, and they must straddle the timing of the recurrence of the glioma tumor.  Step (a), the dendritic cell vaccination, must occur first and specifically be before the tumor recurrence, and step (b) must follow step (a) and specifically be after the tumor recurrence.  The '090 patent is limited to this precise sequence and timing. 

Cedars Sinai/IMUC tried
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... PharmaVentures announced today that it was delighted to act ... Canada as Merck & Co) to secure its deal with ... Roslin BioCentre, for the former MSD research facility in Newhouse, ... MSD, the Scottish Life Sciences community and the Scottish Government. ...
...   Reportlinker.com announces that a new market ... , Strategic Analysis of the Collagen ... http://www.reportlinker.com/p0760990/Strategic-Analysis-of-the-Collagen-Peptide-Market-in-the-United-States.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biomaterial This ... peptides. The historical period is from 2007, ...
... MECHANICSBURG, Pa., Jan. 18, 2012  Select Medical announced it ... Specialists, a well-known provider of physical therapy in the ... Select Medical family with a 25-year reputation for providing ... First Choice and another Select Medical brand known as ...
Cached Biology Technology:PharmaVentures Helps Secure Investor for Former MSD Research Site 2Strategic Analysis of the Collagen Peptide Market in the United States 2First Choice Rehabilitation Specialists Joins Select Medical 2
(Date:7/24/2014)... of how wildlife loss leads to conflict among people ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of ... an interdisciplinary approach to tackle global biodiversity decline. , ... of the world,s people and provides protein for more ... come as no surprise that today,s unprecedented loss of ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... Acoustic disturbance has different effects on different species ... the Universities of Bristol and Exeter which tested ... sooner to a flying seagull predator model when ... observed in European minnows. , Lead author ... Sciences said: "Noise levels in many aquatic environments ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Finland, have identified a blood-flow glucose consumption mismatch that ... study published in Clinical Cancer Research , a ... Based on these findings, they suggested that the ... important information about a tumor than just looking at ...
... can monitor chemical processes or equipment activity and then ... many facilities that could benefit from the use of ... instead, because the reliability, speed and security of the ... needs. The U.S. Department of Energy,s Savannah ...
... forest the boreal forest across large stretches of ... increasing threat, a team of international researchers has found. ... Canada, University of Adelaide in Australia and the National ... of existing boreal forests in order to secure biodiversity ...
Cached Biology News:Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3World's last great forest under threat: New study 2